No Detail Found!

Intravesical Gemcitabine Versus Mitomycin C for Non-Muscle Invasive Bladder Cancer: A Robust Meta-Analysis Revealing Superior Recurrence Control and Improved Tolerability

Author(s)
Mohamed S. Imam Department of Pharmacy, Alnahda College, Riyadh 13255, Kingdom of Saudi Arabia
Manar Mesfer Eid Alsaadi College of Pharmacy, Taif University, Taif 21944, Saudi Arabia
Hadeel S. Althagafi College of Pharmacy, Taif University, Taif 21944, Saudi Arabia
Norah Khalid Abdullah Humaish College of Pharmacy, Taif University, Taif 21944, Saudi Arabia
Atheer Zayed Safar Alotaibi College of Pharmacy, Taif University, Taif 21944, Saudi Arabia
Amjad Homoud Masoud Alotaibi College of Pharmacy, Taif University, Taif 21944, Saudi Arabia
Lujain Mneef Salm Almalki College of Pharmacy, Taif University, Taif 21944, Saudi Arabia
Daniyah Mansour Abdulaziz Alazwari College of Pharmacy, Taif University, Taif 21944, Saudi Arabia
Mahdi Mohammed Ahmed Aljamaan College of Clinical Pharmacy, King Faisal University, Al-Ahsa 31982, Eastern Province, Saudi Arabia
Latifa Fahad Abdalwahap Almohsin College of Clinical Pharmacy, King Faisal University, Al-Ahsa 31982, Eastern Province, Saudi Arabia
Haliah Khaliad Mohamed Alfayez College of Pharmacy, Princess Nourah Bint Abdulrahman University, Riyadh 11671, Saudi Arabia
Lama A. Alamri Specialized Medical Center Healthcare, Riyadh 12311, Saudi Arabia
Myasah Musleh Saif Altamimi College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia
Bashayer Ali Alkhathlan College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia
Khalid Sultan Allahyani College of Pharmacy, Umm Al-Qura University, Makkah 24381, Saudi Arabia
Abstract
Background: Non-Muscle Invasive Bladder Cancer (NMIBC) constitutes the majority of bladder cancer patients but has elevated recurrence rates after intravesical treatment. Although mitomycin C (MMC) is extensively used, intravesical gemcitabine (GCB) has shown potential as a superior option with enhanced tolerability. Objective: This meta-analysis compares the effectiveness and safety of intravesical GCB versus MMC for NMIBC management. Methods: Following PRISMA guidelines, seven studies with 491 patients were analyzed. Outcomes included tumor recurrence, chemical cystitis and hematuria. Fixed-effects or random-effects models were used to compute pooled Odds Ratios (ORs) with 95% Confidence Intervals (CIs). Results: GCB significantly reduced recurrence rates compared to MMC (OR: 2.97; 95% CI: 1.90-4.65; p<0.00001) with low heterogeneity (I² = 13%). The risk of chemical cystitis was also significantly lower with GCB (OR: 4.39; 95% CI: 2.27-8.51; p<0.0001). No significant difference was found in hematuria incidence (OR: 1.71; 95% CI: 0.68-4.33; p = 0.26). Conclusions: Intravesical GCB demonstrates superior efficacy in reducing recurrence and is associated with fewer adverse effects than MMC, supporting its use as a first-line option for NMIBC, especially in patients at risk of recurrence or intolerance to MMC. Further large-scale trials are recommended to confirm these findings and refine treatment strategies.
Publication Details
Page(s) 1-11
DOI DOI not available
Published Journal: Journal of Pioneering Medical Sciences, Volume: 15, Issue: 1, Year: 2026

Request the full text from PASTIC

Keywords
Mitomycin, Meta-analysis, Tumor Recurrence, Non-muscle invasive bladder cancer, Intravenous therapy, Gemcitabine
References
Dyrskjøt L. .2023 .. Bladder Cancer.” Nature Reviews Disease Primers, 9(1) : .
Lobo N. .2022 .Epidemiology, Screening and Prevention of Bladder Cancer. European Urology Oncology, 10(2022) : 628-639.
Tran L. . .. Advances in Bladder Cancer Biology and Therapy.” Nature Reviews Cancer, 21(2021) : 104-121.
Olislagers M. . .Molecular Biomarkers of Progression in Non-Muscle-Invasive Bladder Cancer-Beyond Conventional Risk Stratification. Nature Reviews Urology, 22(2025) : 75-91.
Bell S.D. .2025 .Squamous Cell Bladder Cancer: A Rare Histological Variant with a Demand for Modern Cancer Therapeutics. ” Cancers, 17(2) : .
Dolgasheva D.S. .2024 .Human Papillomavirus and Bladder Cancer: Literature Review and Meta-Analysis. African Journal of Urology, 30(1) : .
Devlies W. .2023 .The Diagnostic Accuracy of Cystoscopy for Detecting Bladder Cancer in Adults Presenting with Haematuria. ” European Urology Focus, 08(2024) : 115-122.
Chou W.H.,Investigations Original .2021 .Cyclophosphamide-Associated Bladder Cancers and Considerations for Survivorship Care. , : .
Abbas N.F. .2023 .Uncovering the Epidemiology of Bladder Cancer in the Arab World. Asian Journal of Urology, 10(2024) : 406-422.
Saginala K. .2020 .. Epidemiology of Bladder Cancer.” Medical Sciences, 8(1) : .
Siegel R.L. .2021 .A Cancer Journal for Clinicians. Cancer Statistics, 71(2021) : 7-33.
Sung H. .2020 .A Cancer Journal for Clinicians. Global Cancer Statistics, 71(2021) : 209-249.
Mushtaq J. .2019 .. Bladder Cancer.” Surgery (Oxford), 07(2019) : 529-537.
Chang S.S. .2016 .Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer. The Journal of Urology, 06(2016) : 1021-1029.
Ma .2023 .“Long-Term Recurrence Rates of Low-Risk NonMuscle-Invasive Bladder Cancer. European Urology Focus, 06(2024) : 189-196.
Thomas J. .2024 .. Impact of BMI Category on Recurrence and Progression of Nonmuscle Invasive Bladder Cancer.” Clinical Genitourinary Cancer, 102286(1) : .
Oszczudlowski M.,Dobruch J. .2018 .Prediction of Progression to Muscle-Invasive Disease. ” Translational Andrology and Urology, 06(4) : .
Filon M.,Schmidt B. .2025 .New Treatment Options for NonMuscle-Invasive Bladder Cancer.” ASCO Educational Book. , 45(2) : .
Teoh J.Y.C. . .Recurrence Mechanisms of Non-MuscleInvasive Bladder Cancer. Nature Reviews Urology, 19(2022) : 280-294.
Bryan R.T. . .Mechanisms of Recurrence of Ta/T1 Bladder Cancer.” Annals of the Royal College of Surgeons of England. , 92(2010) : 519-524.
Liu W. .2024 .Recurrence and Prevention Strategies for NonMuscle-Invasive Bladder Cancer: A Comprehensive Review. Asian Journal of Urology, 12 : .
Wiesen B. .2025 .Updated Review on Novel Therapies and Ongoing Clinical Trials for High-Risk Non-Muscle Invasive Bladder Cancer. , 1519428 : .
Whelan P. “ .2007 .The Treatment of Non-Muscle-Invasive Bladder Cancer with Intravesical Chemotherapy and Immunotherapy. European Urology Supplements, 01(2007) : 568-571.
Scilipoti P.,Meta-Analysis P. .2024 .The Role of Mitomycin C in IntermediateRisk Non-Muscle-Invasive Bladder Cancer: A Systematic Review. ” European Urology Oncology, 06 : .
Zargar H. .2014 .Optimizing Intravesical Mitomycin C Therapy in Non-Muscle-Invasive Bladder Cancer. Nature Reviews Urology, 52(2014) : 220-230.
Gederaas O.A. .2014 .Increased Anticancer Efficacy of Intravesical Mitomycin C Therapy when Combined with a PCNA Targeting Peptide. Translational Oncology, 10(6) : .
.2022 .Effect of Intravesical Mitomycin Compared with Gemcitabine on the Treatment of Non-Muscle Invasive Bladder Cancer: A Meta-Analysis.” Actas Urológicas Españolas (English Edition). , 12(2023) : 92-98.
Shao .2022 .Clinical Efficacy of Intravesical Gemcitabine Combined with Ubenimex in Patients with Non-MuscleInvasive Bladder Carcinoma. Pakistan Journal of Medical Sciences, 38(5) : .
Du W. .2024 .UPP1 Enhances Bladder Cancer Progression and Gemcitabine Resistance through AKT. International Journal of Biological Sciences, 20(4) : .
Stadler W.M. .1997 .Phase II Study of Single-Agent Gemcitabine in Previously Untreated Patients with Metastatic Urothelial Cancer. ” Journal of Clinical Oncology, 15(11) : 3394-3398.
Beutel A.K.,Halbrook C.J. .2022 .Barriers and Opportunities for Gemcitabine in Pancreatic Cancer Therapy. American Journal of Physiology-Cell Physiology, 324(2023) : C540-C552.
Bastiancich C. .2017 .. Gemcitabine and Glioblastoma: Challenges and Current Perspectives.” Drug Discovery Today, 10(2018) : 416-423.
Prasanna T. .2017 .Intravesical Gemcitabine versus Intravesical Bacillus Calmette-Guérin for Non-Muscle Invasive Bladder Cancer. , 00260 : .
Li R. .2020 .Intravesical Gemcitabine versus Mitomycin for Non-Muscle Invasive Bladder Cancer. BMC Urology, 20 : 1-8.
Gupta A. . .Obesity Is Independently Associated with Increased Risk of Hepatocellular Cancer-Related Mortality. American Journal of Clinical Oncology, 41(2018) : 0000000000-000388.
Xiaohong Z. .2015 .Clinical Effect of Antineoplastic Drug Perfusion in Preventing Postoperative Recurrence of Superficial Bladder Cancer. ” Journal of Chinese Physician, 17 : 1043-1045.
Lin T.,Sun L. .2016 .Comparison of the Efficacy of Different Chemotherapy Drugs in Preventing Postoperative Recurrence of Superficial Bladder Cancer. China Foreign Medical Treatment, 35 : 118-119.
Sun S. .2016 .Comparison of Intravesical Perfusion of Gemcitabine and Mitomycin after Non-Muscle Invasive Bladder Cancer. ” Journal of Medical Theory and Practice, 29 : 3238-3239.
Dong X. .2017 .Curative Effect Analysis of Different Chemotherapeutics at Intravesical Instillation after TUR-Bt. Zhejiang Journal of Traumatic Surgery, 22 : 109-110.
Addeo R. .2008 .Randomized Phase III Trial on Gemcitabine versus Mitomycin in Recurrent Superficial Bladder Cancer. ” Journal of Clinical Oncology, 20(2010) : 543-548.
Alam S. . .Intravesical Gemcitabine and Mitomycin C Chemotherapy in Non-Muscle Invasive Transitional Cell Carcinoma. Bangladesh Journal of Urology, 22(2019) : 50071-29.
Chaaya Abou,C. Abou .2024 .Comparing Efficacy and Safety of InHouse Gemcitabine to Mitomycin for Bladder Instillation. The French Journal of Urology, 102699(13) : .
Shelley M.D. .2011 .Intravesical Gemcitabine Therapy for Non-Muscle Invasive Bladder Cancer. , 10880(2012) : 1464-410X.
Messing E.M. .2018 .Effect of Intravesical Gemcitabine vs Saline after Resection of Low-Grade Bladder Cancer. ” JAMA, 4657(18) : 1880-1888.
Dalbagni G. .2005 .Phase II Trial of Intravesical Gemcitabine in BCG-Refractory Bladder Cancer. ” Journal of Clinical Oncology, 05(18) : 2729-2734.
Bartoletti R. .2005 .Intravesical Gemcitabine Therapy for Superficial Transitional Cell Carcinoma. ” Urology, 04(2005) : 726-731.
Matloubieh J.E. .2024 .Comparisons of Intravesical Treatments with Mitomycin C, Gemcitabine. ” Cancers, 16(24) : .
Cockerill P.A. . .Intravesical Gemcitabine Combined with Mitomycin C as Salvage Treatment. , 117(2016) : 456-462.
Lightfoot A.J. .2014 .Sequential Intravesical Gemcitabine and Mitomycin C for Bladder Cancer. Urologic Oncology: Seminars and Original Investigations, : .
Zeng J. .2023 .Gemcitabine as First-Line Therapy for HighGrade Non-Muscle Invasive Bladder Cancer. Translational Andrology and Urology, 12(6) : .
0

Citations

0

Downloads

16

Views